William Blair rates PDL BioPharma market perform

PDL BioPharma was assigned a market perform rating and company profile of aggressive growth with earnings-per-share estimates of $0.41, $0.68 and $1.22 in fiscal 2006, 2007 and 2008, respectively, by William Blair & Co. analyst John Sonnier, who predicted that revenue from the company's newly acquired specialty franchise will grow by 57% to $190 million in 2006 and that royalty revenue will increase by 40% to $182 million in 2006. Shares of the Fremont, Calif.-based biopharmaceutical company were down 53 cents, or 1.67%, at $31.26 on volume of 677,489 shares versus the three-month running average of 1,538,790 shares. (Nasdaq: PDLI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.